• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018.

作者信息

Dinnessen Manette A W, Visser Otto, Tonino Sanne H, Posthuma Eduardus F M, Blijlevens Nicole M A, Kersten Marie José, Lugtenburg Pieternella J, Dinmohamed Avinash G

机构信息

Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands.

出版信息

Blood Cancer J. 2021 Nov 13;11(11):179. doi: 10.1038/s41408-021-00574-5.

DOI:10.1038/s41408-021-00574-5
PMID:34775466
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8590687/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb1b/8590687/96044ec45b34/41408_2021_574_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb1b/8590687/96044ec45b34/41408_2021_574_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb1b/8590687/96044ec45b34/41408_2021_574_Fig1_HTML.jpg

相似文献

1
Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018.滤泡性淋巴瘤患者发生第二原发性恶性肿瘤的风险：1989 - 2018年荷兰的一项基于人群的研究。
Blood Cancer J. 2021 Nov 13;11(11):179. doi: 10.1038/s41408-021-00574-5.
2
Histological transformation and secondary malignancies in follicular lymphoma.滤泡性淋巴瘤中的组织学转化与继发性恶性肿瘤
Lancet Haematol. 2018 Nov;5(11):e496-e497. doi: 10.1016/S2352-3026(18)30170-4.
3
Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.滤泡性淋巴瘤患者继发血液系统恶性肿瘤的风险：利妥昔单抗时代 1028 例患者的分析。
Br J Haematol. 2019 Nov;187(3):364-371. doi: 10.1111/bjh.16090. Epub 2019 Jul 3.
4
Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.利妥昔单抗时代日本晚期滤泡性淋巴瘤患者生存时间、组织学转化及继发性恶性肿瘤的长期调查：北海道血液学研究组
Int J Hematol. 2014 Sep;100(3):281-9. doi: 10.1007/s12185-014-1629-4. Epub 2014 Jul 23.
5
Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status.弥漫性大B细胞淋巴瘤与同时或先前存在的滤泡性淋巴瘤及双打击状态相关的生存结果。
Leuk Lymphoma. 2019 Dec;60(13):3266-3271. doi: 10.1080/10428194.2019.1622099. Epub 2019 Jun 21.
6
Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.滤泡性淋巴瘤患者发生第二原发性恶性肿瘤的风险：一项基于美国人群的研究。
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):569-574. doi: 10.1016/j.clml.2017.06.028. Epub 2017 Jun 24.
7
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.初治晚期滤泡性淋巴瘤患者接受R-CHOP方案治疗后的结局：JCOG0203试验的10年随访分析
Lancet Haematol. 2018 Nov;5(11):e520-e531. doi: 10.1016/S2352-3026(18)30155-8.
8
Sub-clinical dissemination of follicular lymphoma in normal sized lymph nodes may not be detected by radiologic staging: a case of disseminated follicular lymphoma detected in nodal clearance as part of therapy for cutaneous melanoma.正常大小淋巴结中滤泡性淋巴瘤的亚临床播散可能无法通过影像学分期检测到：一例在皮肤黑色素瘤治疗中作为淋巴结清扫一部分而发现的播散性滤泡性淋巴瘤病例。
Leuk Lymphoma. 2006 Mar;47(3):553-6. doi: 10.1080/10428190500305596.
9
Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.美国滤泡性淋巴瘤的二线及后续治疗与结局：来自观察性全国淋巴瘤护理研究的数据
Br J Haematol. 2019 Feb;184(4):660-663. doi: 10.1111/bjh.15149. Epub 2018 Apr 2.
10
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.钇-90替伊莫单抗巩固治疗氟达拉滨、米托蒽醌、利妥昔单抗用于中/高危滤泡性淋巴瘤：中位随访7年后的长期结果更新
Cancer Med. 2016 Jun;5(6):1093-7. doi: 10.1002/cam4.684. Epub 2016 Mar 14.

引用本文的文献

1
Risk and prognosis of second primary malignancies in patients with follicular lymphoma in the era of rituximab: A population study based on the SEER database.利妥昔单抗时代滤泡性淋巴瘤患者第二原发性恶性肿瘤的风险与预后：一项基于监测、流行病学和最终结果（SEER）数据库的人群研究
PLoS One. 2025 May 28;20(5):e0324532. doi: 10.1371/journal.pone.0324532. eCollection 2025.
2
Survival analysis of a 16-year cohort of follicular lymphoma patients receiving systemic treatment in Brazil.巴西接受全身治疗的滤泡性淋巴瘤患者16年队列的生存分析。
Front Pharmacol. 2025 Jan 10;15:1414244. doi: 10.3389/fphar.2024.1414244. eCollection 2024.
3

本文引用的文献

1
The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population-based study.既往恶性肿瘤对滤泡性淋巴瘤患者发生第二原发性恶性肿瘤及生存的影响：一项基于人群的研究。
EJHaem. 2020 Oct 8;1(2):489-497. doi: 10.1002/jha2.108. eCollection 2020 Nov.
2
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发滤泡性淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Mar;32(3):298-308. doi: 10.1016/j.annonc.2020.11.008. Epub 2020 Nov 26.
3
Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016.
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
弥漫性大 B 细胞淋巴瘤五年幸存者中特定治疗后恶性肿瘤的发生风险。
ESMO Open. 2024 Feb;9(2):102248. doi: 10.1016/j.esmoop.2024.102248. Epub 2024 Feb 12.
4
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019.慢性淋巴细胞白血病患者的二次原发性恶性肿瘤风险：1989-2019 年荷兰基于人群的研究。
Blood Cancer J. 2023 Jan 13;13(1):15. doi: 10.1038/s41408-023-00784-z.
5
Trends in the risk of second primary malignances after non-Hodgkin's lymphoma.非霍奇金淋巴瘤后第二原发性恶性肿瘤风险的趋势。
Am J Cancer Res. 2022 Jun 15;12(6):2863-2875. eCollection 2022.
滤泡性淋巴瘤的初始治疗和生存的阶段特异性趋势：荷兰全国基于人群的分析，1989-2016 年。
Leukemia. 2021 Jun;35(6):1683-1695. doi: 10.1038/s41375-020-01048-6. Epub 2020 Oct 12.
4
The Immune System and Pathogenesis of Melanoma and Non-melanoma Skin Cancer.免疫系统与黑色素瘤和非黑色素瘤皮肤癌的发病机制。
Adv Exp Med Biol. 2020;1268:211-226. doi: 10.1007/978-3-030-46227-7_11.
5
The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer.B 淋巴细胞在非小细胞肺癌免疫生物学中的作用。
Cancer Immunol Immunother. 2020 Mar;69(3):325-342. doi: 10.1007/s00262-019-02461-2. Epub 2020 Jan 4.
6
Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.滤泡性淋巴瘤患者继发血液系统恶性肿瘤的风险：利妥昔单抗时代 1028 例患者的分析。
Br J Haematol. 2019 Nov;187(3):364-371. doi: 10.1111/bjh.16090. Epub 2019 Jul 3.
7
The Role of the Immune System in Cutaneous Squamous Cell Carcinoma.免疫系统在皮肤鳞状细胞癌中的作用。
Int J Mol Sci. 2019 Apr 24;20(8):2009. doi: 10.3390/ijms20082009.
8
Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.滤泡性淋巴瘤患者发生第二原发性恶性肿瘤的风险：一项基于美国人群的研究。
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):569-574. doi: 10.1016/j.clml.2017.06.028. Epub 2017 Jun 24.
9
Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.现代治疗时代弥漫性大B细胞淋巴瘤后的后续原发性恶性肿瘤。
Br J Haematol. 2017 Jul;178(1):72-80. doi: 10.1111/bjh.14638. Epub 2017 May 25.
10
Radiation exposure and thyroid cancer: a review.辐射暴露与甲状腺癌：综述
Arch Endocrinol Metab. 2017 Mar-Apr;61(2):180-187. doi: 10.1590/2359-3997000000257. Epub 2017 Feb 16.